(Q36327410)

13 August 2017

1 reference

title

Clinical trials in ALS: a review of the role of clinical and neurophysiological measurements (English)

1 reference

amyotrophic lateral sclerosis

13 August 2017

main subject

1 reference

1 reference

Michael Swash

3

0 references

Mamede de Carvalho

series ordinal

1

object named as

Mamede de Carvalho

1 reference

13 August 2017

João Costa

2

1 reference

13 August 2017

publication date

1 December 2005

1 reference

Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases

13 August 2017

published in

1 reference

13 August 2017

volume

6

1 reference

13 August 2017

issue

4

1 reference

13 August 2017

page(s)

202-212

1 reference

Clinical trials in ALS: an overview.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Consensus guidelines for the design and implementation of clinical trials in ALS. World Federation of Neurology committee on Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Recombinant growth hormone treatment of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

A controlled trial of amino acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. WALS Study Group. Western Amyotrophic Lateral Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: results of two phase III trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

A clinical trial of creatine in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Clinical and neurophysiological evaluation of progression in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Nutritional assessment and survival in ALS patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

The natural history of motoneuron loss in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Functional outcome measures as clinical trial endpoints in ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Health outcome and quality-of-life measurements in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

ALS trial design: expectation and reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Therapeutic trial of tilorone in ALS: Lack of benefit in a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Ganglioside therapy for amyotrophic lateral sclerosis: a double-blind controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Amyotrophic lateral sclerosis: a double-blind crossover trial of thyrotropin-releasing hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Chronic treatment with L-threonine in amyotrophic lateral sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

A pilot trial of dextromethorphan in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Evaluation of electrophysiological and clinical tests in an exploratory trial of Org 2766 in motor neuron disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Controlled trial of nimodipine in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Electrophysiologic endpoint measures in a multicenter ALS drug trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

The use of statistical MUNE in a multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

Quantitating progression in ALS

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14660820510011997

10.1080/14660820510011997

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference